Aileron Therapeutics Inc (OQ:ALRN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 738 Main Street, Unit 398
WALTHAM MA 02451
Tel: N/A
Website: https://aileronrx.com
IR: See website
<
Key People
Brian Windsor
President, Chief Executive Officer, Director
Susan L. Drexler
Interim Chief Financial Officer
 
Business Overview
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Financial Overview
For the nine months ended 30 September 2023, Aileron Therapeutics Inc revenues was not reported. Net loss decreased 63% to $8.4M. Lower net loss reflects Research and development decrease of 88% to $1.8M (expense), General and administrative decrease of 14% to $5.3M (expense), Stock-based Compensation in SGA decrease of 42% to $693K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$5.02 to -$1.85.
Employees: 6 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $21.79M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$12.64M as of Sep 30, 2023
Net annual income (TTM): -$12.94M as of Sep 30, 2023
Free cash flow (TTM): -$13.83M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 4,885,512 as of Jan 18, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.